Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO IYII) epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1024-1031

  Dur Skírnisdóttir, Ingirí ^a,c   Seidal, Tomas ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Halmstad Medical Center Hospital   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early stages; Ovarian cancer; p53; p53 PTEN; Prognosis; PTEN; Serous tumors

Indexed keywords

CARBOPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; SWEDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 83055165668     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821dc906     Document Type: Article

References (24)

1. Kurman RJ, Visvanathan K, Roden R, et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008;4:351Y356. (Pubitemid 351451941)
2. Aletti GD, Gostout BS, Podratz KC, et al. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:31Y37.
3. Hennessy BT, Markman M. Development of novel agents for ovarian cancer. Update Cancer Ther. 2009;3:119Y132.
4. Takei Y, Saga Y, Mizukami H, et al. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol Cancer Ther. 2008;7:704Y711. (Pubitemid 351482153)
5. Palmer JE, Sant Cassia LJ, Irwin CJ, et al. p53 and bcl-2 assessment in serous carcinoma. J Gynecol Cancer. 2008; 18:241Y248. (Pubitemid 351365201)
6. Lee Y-K, Park N-H. Prognostic value and clinico-pathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol. 2009;112:475Y480.
7. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol. 2006;103:692Y697. (Pubitemid 44602189)
8. Yan X, Fraser M, Qiu Q, et al. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006;103:692Y697.
9. Skirnisdottir I, Sorbe B, Seidal T. p53, bcl-2, bax; their relationship and effect on prognosis in early stage ovarian carcinoma. Int J Gynecol Cancer. 2001;11:241Y248.
10. Lassus H, Leminen A, Lundin J, et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003;91:504Y512. (Pubitemid 38388142)
11. Skirnisdottir I, Sorbe B, Seidal T. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int J Gynecol Cancer. 2004; 14:259Y270. (Pubitemid 38533897)
12. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European Organisation for Research and Treatment of CancerVAdjuvant Chemotherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst. 2003;95:113Y125. (Pubitemid 36193260)
13. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844Y847. (Pubitemid 28331029)
14. Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001; 25:1204Y1207. (Pubitemid 32777722)
15. Darcy KM, Brady WE, McBroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelian ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;111:478Y495.
16. Kurose K, Zhou X-P, Araki T, et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001; 158:2097Y2106. (Pubitemid 32545195)
17. Köbel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol. 2010;116:50Y56.
18. Berchuck A, Iversen ES, Luo J, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favourable outcome. Clin Cancer Res. 2009;15:2448Y2455.
19. Chien J, Fan JB, Bell DA, et al. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009;114:3Y11.
20. Bourdon JC. P53 and its isoforms in cancer. Br J Cancer. 2007;97:277Y282.
21. Deyoung MP, Ellisen LW. p63 and p73 in human cancer. Defining the network. Oncogen. 2007;26:5169Y5183. (Pubitemid 47237632)
22. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317Y325. (Pubitemid 32831549)
23. Kim JS, Lee C, Bonnifant CL, et al. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2007;27:662Y677. (Pubitemid 46080132)
24. Cully M, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184Y192. (Pubitemid 43292562)